COMPASS Pathways (NASDAQ:CMPS) Rating Reiterated by Cantor Fitzgerald

COMPASS Pathways (NASDAQ:CMPS)‘s stock had its “overweight” rating reissued by analysts at Cantor Fitzgerald in a report released on Tuesday, Benzinga reports.

A number of other brokerages have also commented on CMPS. HC Wainwright restated a “buy” rating and issued a $120.00 price target on shares of COMPASS Pathways in a report on Friday, March 1st. Morgan Stanley began coverage on COMPASS Pathways in a report on Monday, April 1st. They set an “overweight” rating and a $30.00 target price on the stock. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, COMPASS Pathways presently has a consensus rating of “Buy” and an average price target of $47.40.

COMPASS Pathways Stock Performance

Shares of COMPASS Pathways stock opened at $8.48 on Tuesday. The firm has a market cap of $525.25 million, a price-to-earnings ratio of -3.55 and a beta of 2.48. The stock’s 50-day moving average is $9.57 and its 200-day moving average is $8.46. COMPASS Pathways has a one year low of $5.01 and a one year high of $12.75. The company has a debt-to-equity ratio of 0.14, a current ratio of 13.33 and a quick ratio of 13.33.

COMPASS Pathways (NASDAQ:CMPS) last issued its quarterly earnings results on Thursday, February 29th. The company reported ($0.53) EPS for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.16). Equities analysts predict that COMPASS Pathways will post -2.4 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, major shareholder George Jay Goldsmith sold 23,881 shares of the company’s stock in a transaction dated Tuesday, April 16th. The stock was sold at an average price of $8.53, for a total transaction of $203,704.93. Following the sale, the insider now owns 3,986,523 shares in the company, valued at $34,005,041.19. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other COMPASS Pathways news, Director Ekaterina Malievskaia sold 19,853 shares of the company’s stock in a transaction that occurred on Tuesday, February 6th. The stock was sold at an average price of $10.59, for a total value of $210,243.27. Following the sale, the director now owns 4,144,994 shares in the company, valued at $43,895,486.46. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder George Jay Goldsmith sold 23,881 shares of the company’s stock in a transaction that occurred on Tuesday, April 16th. The shares were sold at an average price of $8.53, for a total value of $203,704.93. Following the completion of the sale, the insider now owns 3,986,523 shares in the company, valued at approximately $34,005,041.19. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 140,601 shares of company stock worth $1,338,911. Corporate insiders own 4.25% of the company’s stock.

Institutional Trading of COMPASS Pathways

Institutional investors and hedge funds have recently bought and sold shares of the business. ARK Investment Management LLC grew its position in shares of COMPASS Pathways by 7.6% in the fourth quarter. ARK Investment Management LLC now owns 2,618,871 shares of the company’s stock valued at $22,915,000 after purchasing an additional 186,040 shares during the last quarter. Vivo Capital LLC acquired a new position in shares of COMPASS Pathways in the third quarter valued at approximately $11,899,000. RA Capital Management L.P. acquired a new position in shares of COMPASS Pathways in the third quarter valued at approximately $9,516,000. Affinity Asset Advisors LLC acquired a new position in shares of COMPASS Pathways in the fourth quarter valued at approximately $4,812,000. Finally, Laurion Capital Management LP grew its position in shares of COMPASS Pathways by 169.7% in the third quarter. Laurion Capital Management LP now owns 510,907 shares of the company’s stock valued at $3,781,000 after purchasing an additional 321,500 shares during the last quarter. Institutional investors own 46.19% of the company’s stock.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.